Connor, Clark & Lunn Investment Management (CC&L)’s SELLAS Life Sciences SLS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324K	Buy	+21,921	New	+$151K	﹤0.01%	1483

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Connor, Clark & Lunn Investment Management (CC&L)'s SLS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 21,921 shares worth $324K. The stake represents ﹤0.01% of the portfolio and ranks #1483 among its holdings.

192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 21,921 shares of SELLAS Life Sciences worth $324K as of Q2 2026.
SELLAS Life Sciences was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
SELLAS Life Sciences made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1483 holding.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.